scholarly journals Multivariate Analysis for the Classification of Chocolate According to its Percentage of Cocoa by Using Terahertz Time-Domain Spectroscopy (THz-TDS)

Proceedings ◽  
2020 ◽  
Vol 70 (1) ◽  
pp. 109
Author(s):  
Jimy Oblitas ◽  
Jorge Ruiz

Terahertz time-domain spectroscopy is a useful technique for determining some physical characteristics of materials, and is based on selective frequency absorption of a broad-spectrum electromagnetic pulse. In order to investigate the potential of this technology to classify cocoa percentages in chocolates, the terahertz spectra (0.5–10 THz) of five chocolate samples (50%, 60%, 70%, 80% and 90% of cocoa) were examined. The acquired data matrices were analyzed with the MATLAB 2019b application, from which the dielectric function was obtained along with the absorbance curves, and were classified by using 24 mathematical classification models, achieving differentiations of around 93% obtained by the Gaussian SVM algorithm model with a kernel scale of 0.35 and a one-against-one multiclass method. It was concluded that the combined processing and classification of images obtained from the terahertz time-domain spectroscopy and the use of machine learning algorithms can be used to successfully classify chocolates with different percentages of cocoa.

2020 ◽  
Vol 57 (23) ◽  
pp. 233001
Author(s):  
章龙 Zhang Long ◽  
李春 Li Chun ◽  
李天莹 Li Tianying ◽  
张岩 Zhang Yan ◽  
蒋玲 Jiang Ling

PLoS ONE ◽  
2021 ◽  
Vol 16 (7) ◽  
pp. e0254181
Author(s):  
Kamila Lis ◽  
Mateusz Koryciński ◽  
Konrad A. Ciecierski

Data classification is one of the most commonly used applications of machine learning. The are many developed algorithms that can work in various environments and for different data distributions that perform this task with excellence. Classification algorithms, just like other machine learning algorithms have one thing in common: in order to operate on data, they must see the data. In the present world, where concerns about privacy, GDPR (General Data Protection Regulation), business confidentiality and security are growing bigger and bigger; this requirement to work directly on the original data might become, in some situations, a burden. In this paper, an approach to the classification of images that cannot be directly accessed during training has been made. It has been shown that one can train a deep neural network to create such a representation of the original data that i) without additional information, the original data cannot be restored, and ii) that this representation—called a masked form—can still be used for classification purposes. Moreover, it has been shown that classification of the masked data can be done using both classical and neural network-based classifiers.


2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
H Lea ◽  
E Hutchinson ◽  
A Meeson ◽  
S Nampally ◽  
G Dennis ◽  
...  

Abstract Background and introduction Accurate identification of clinical outcome events is critical to obtaining reliable results in cardiovascular outcomes trials (CVOTs). Current processes for event adjudication are expensive and hampered by delays. As part of a larger project to more reliably identify outcomes, we evaluated the use of machine learning to automate event adjudication using data from the SOCRATES trial (NCT01994720), a large randomized trial comparing ticagrelor and aspirin in reducing risk of major cardiovascular events after acute ischemic stroke or transient ischemic attack (TIA). Purpose We studied whether machine learning algorithms could replicate the outcome of the expert adjudication process for clinical events of ischemic stroke and TIA. Could classification models be trained on historical CVOT data and demonstrate performance comparable to human adjudicators? Methods Using data from the SOCRATES trial, multiple machine learning algorithms were tested using grid search and cross validation. Models tested included Support Vector Machines, Random Forest and XGBoost. Performance was assessed on a validation subset of the adjudication data not used for training or testing in model development. Metrics used to evaluate model performance were Receiver Operating Characteristic (ROC), Matthews Correlation Coefficient, Precision and Recall. The contribution of features, attributes of data used by the algorithm as it is trained to classify an event, that contributed to a classification were examined using both Mutual Information and Recursive Feature Elimination. Results Classification models were trained on historical CVOT data using adjudicator consensus decision as the ground truth. Best performance was observed on models trained to classify ischemic stroke (ROC 0.95) and TIA (ROC 0.97). Top ranked features that contributed to classification of Ischemic Stroke or TIA corresponded to site investigator decision or variables used to define the event in the trial charter, such as duration of symptoms. Model performance was comparable across the different machine learning algorithms tested with XGBoost demonstrating the best ROC on the validation set for correctly classifying both stroke and TIA. Conclusions Our results indicate that machine learning may augment or even replace clinician adjudication in clinical trials, with potential to gain efficiencies, speed up clinical development, and retain reliability. Our current models demonstrate good performance at binary classification of ischemic stroke and TIA within a single CVOT with high consistency and accuracy between automated and clinician adjudication. Further work will focus on harmonizing features between multiple historical clinical trials and training models to classify several different endpoint events across trials. Our aim is to utilize these clinical trial datasets to optimize the delivery of CVOTs in further cardiovascular drug development. FUNDunding Acknowledgement Type of funding sources: Private company. Main funding source(s): AstraZenca Plc


2021 ◽  
Vol 11 (9) ◽  
pp. 881
Author(s):  
Rassanee Bissanum ◽  
Sitthichok Chaichulee ◽  
Rawikant Kamolphiwong ◽  
Raphatphorn Navakanitworakul ◽  
Kanyanatt Kanokwiroon

Triple negative breast cancer (TNBC) lacks well-defined molecular targets and is highly heterogenous, making treatment challenging. Using gene expression analysis, TNBC has been classified into four different subtypes: basal-like immune-activated (BLIA), basal-like immune-suppressed (BLIS), mesenchymal (MES), and luminal androgen receptor (LAR). However, there is currently no standardized method for classifying TNBC subtypes. We attempted to define a gene signature for each subtype, and to develop a classification method based on machine learning (ML) for TNBC subtyping. In these experiments, gene expression microarray data for TNBC patients were downloaded from the Gene Expression Omnibus database. Differentially expressed genes unique to 198 known TNBC cases were identified and selected as a training gene set to train in seven different classification models. We produced a training set consisting of 719 DEGs selected from uniquely expressed genes of all four subtypes. The highest average accuracy of classification of the BLIA, BLIS, MES, and LAR subtypes was achieved by the SVM algorithm (accuracy 95–98.8%; AUC 0.99–1.00). For model validation, we used 334 samples of unknown TNBC subtypes, of which 97 (29.04%), 73 (21.86%), 39 (11.68%) and 59 (17.66%) were predicted to be BLIA, BLIS, MES, and LAR, respectively. However, 66 TNBC samples (19.76%) could not be assigned to any subtype. These samples contained only three upregulated genes (EN1, PROM1, and CCL2). Each TNBC subtype had a unique gene expression pattern, which was confirmed by identification of DEGs and pathway analysis. These results indicated that our training gene set was suitable for development of classification models, and that the SVM algorithm could classify TNBC into four unique subtypes. Accurate and consistent classification of the TNBC subtypes is essential for personalized treatment and prognosis of TNBC.


2018 ◽  
Vol 13 (1) ◽  
pp. 143-160 ◽  
Author(s):  
Panpan Liu ◽  
Xin Zhang ◽  
Baolin Pan ◽  
Mingjian Wei ◽  
Zhuoyong Zhang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document